Eye Care Insider

In this episode, Arthur Benjamin, MD, discusses dry eye treatment and trends, the challenges dry eye patients and the eye care professionals treating them and more.

• Intro :37
• Welcome to another episode of Eye Care insider :51
• About Arthur Benjamin, MD 1:02
• I wonder if you could talk about your training and what you currently do now? 1:39
• Could you talk about what you've seen throughout the years and what you've seen in the trends in dry eye and how it has expanded in the population? 2:56
• What is your current algorithm for someone with dry eye? How do you manage that? 5:01
• Once you do determine they have moderate dry eye where do you start with the patient or the treatment paradigm? 7:00
• With the OptiLight treatment option … what do you tell patients? What should they be expecting? 9:54
• I recently saw that there's been a campaign from OptiLight involving Mandy Moore. Could you talk about that campaign and discuss it a little bit further? 12:54
• What do you think is the most important topic or issue or challenge that are facing dry eye patients today or eye care professionals treating patients with dry eye? 16:07
• What a fascinating discussion 17:43
• Any last words? 17:55
• Outro 18:09

Arthur Benjamin, MD, is a clinical assistant professor at the Jules Stein/Doheny Eye Institute at UCLA's Geffen School of Medicine and is in private practice at Benjamin Eye Institute.

We'd love to hear from you! Send your comments/questions to Dr. Mali at [email protected]. Follow us on Twitter @Healio_OSN. Dr. Benjamin can be contacted by going to BenjaminEye.com.

Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. Benjamin reports no relevant financial disclosures.

In this episode, Dhruvin Patel, MCOptom, discusses the short- and long-term effects of blue light on our eyes, how the pandemic has exacerbated these effects and how his company, Ocushield, is looking to help protect eyes from blue light.

• Intro :01
• Patel's introduction and background :43
• The science and necessity behind blue light blocking filters 5:35
• Short-term effects of blue light on the eyes 7:15
• Long-term effects of blue light on the eyes 8:24
• Are eye care professionals doing enough to promote blue light protection? 12:11
• Has the pandemic affected the demand/awareness of blue light related products? 14:25
• Ocushield filters: what they are and how to get them 16:15
• What makes Ocushield unique in the blue light/ophthalmic landscape? 19:03
• How to contact Dr. Patel and Ocushield 20:31
• Patel's final thoughts on our visual system and the importance of protecting it 21:11
• Outro 22:01

Dhruvin Patel, MCOptom, is an optometrist and the founder of Ocushield. You can send your comments/questions directly to him at www.ocushield.com. Follow him on Instagram, Facebook and Twitter @getocushield.

We'd love to hear from you! Send your comments/questions to Dr. Mali at [email protected]. Follow us on Twitter @Healio_OSN

Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. Patel is founder of Ocushield.

In this episode I share my top 5 predictions in ophthalmology for 2022, including my thoughts on the future of COVID-19 and ocular gene therapy.

• Welcome to another exciting episode of Eye Care insider :50
• My top 5 predictions for 2022 1:16
• Prediction #1 – on COVID-19 1:27
• Prediction #2 – on wet AMD 2:43
• Prediction #3 – on ocular gene therapy 4:05
• Prediction #4 – on geographic atrophy 5:05
• Prediction #5 – on ophthalmology media platforms 7:23
• Thanks for listening 9:20

We'd love to hear from you! Send your comments/questions to Dr. Mali at [email protected]. Follow us on Twitter @Healio_OSN. You can contact Mogan by going to the company's website, www.parkplacepayments.com or at Linkedin.

Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron.

In this episode, Jennifer L. Mogan, MD, discusses her path into medicine, the importance of the credit card process and how it can be beneficial for eyecare practices.

• Welcome to another exciting episode of Eye Care insider :14
• What led to the inception of the 'Doctorpreneurship' series? :29
• About Mogan 2:16
• The interview 2:47
• Give us an idea of your background, your training and why you went to medicine? 3:12
• How in the world did you get involved with credit card processing? 4:12
• Can you summarize the whole credit card processing process? Why should eye care professional or anybody in health care be aware of this structure and how will it affect their bottom line? 5:51
• So, what are you finding in the market? Are physicians aware of this, are they not? And if they're not, how much is this potentially costing a practice? 11:37
• How can they implement these strategies in practice or what services can your company offer eyecare professionals in helping to solve this problem? 12:46
• Have you seen an uptake in business recently because of practices trying to minimize their expenses by lowering these rates? 13:57
• How to find Mogan 14:35
• What do you love about being a Doctorpreneur and do you have any advice or pearls for the audience? 15:02
• Thank you, Dr. Mogan for all your great advice and tips 16:07

Jennifer L. Mogan, MD, is an anesthesiology specialist with Rochester Regional Health and a senior account specialist for Park Place Payments.

We'd love to hear from you! Send your comments/questions to Dr. Mali at [email protected]. Follow us on Twitter @Healio_OSN. You can contact Mogan by going to the company's website, www.parkplacepayments.com or at Linkedin.

Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. Mogan is a senior account specialist for Park Place Payments.

In this episode, Sue Washer, BS, MBA, discusses gene therapy in ophthalmology, ATGC's clinical trial progress, as well as current and future challenges faced by both the cell therapy industry and ophthalmology.

• Welcome to another exciting episode of Eye Care insider :13
• About Washer 1:51
• Can you discuss what is gene therapy? How does it work on a basic level? 4:53
• How do companies like AGTC make gene therapy work for diseases that may not affect as many people but still make it financially successful for investors? 7:11
• Could you talk about where you are in the X-Linked Retinitis Pigmentosa candidate trials? 11:08
• Is there an estimated timeline that you have for initial data read out? 14:56
• You have another candidate for achromatopsia … I was reading you had some new data released. Could you go into more details about that? 16:23
• What do you think is the most important topic or challenge you see facing the gene therapy industry and ophthalmology today and in the future? 20:56
• Thank you so much for your insight into this fascinating topic 23:22
• How to find out more about AGTC 23:31
• Thank you for listening 24:15

Sue Washer, BS, MBA is the president and chief executive officer of AGTC.

We'd love to hear from you! Send your comments/questions to Dr. Mali at [email protected]. Follow us on Twitter @Healio_OSN. You can contact AGTC through the company's website at www.atgc.com.

Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. Washer is the president and CEO of AGTC.

In this episode, the third of a three-part series, John B. Pinto discusses some of the future megatrends expected for ophthalmic practices, challenge practices may face in the future, and more.

• Intro :13
• What you think the megatrends are going to be over the next decade or so in the ophthalmic practices :50
• What do you think is the most important topic or issue or challenge facing ophthalmic practices now and in the future? 4:46
• If our listeners wanted to learn more, what's the best way to contact you? 10:02
• I really appreciate you and all your great advice 10:47
• Any final words? 11:00
• Thank you so much John, I appreciate it 11:16

John B. Pinto is president of J. Pinto & Associates, Inc. He is also a practice consultant and the author of several books on ophthalmic practice management, including John Pinto's Little Green Book of Ophthalmology, UP (with Corinne Wohl), Simple, and Ophthalmic Leadership.

UP: Taking Ophthalmic Administrators and Their Management Teams to the Next Level of Skill, Performance and Career Satisfaction, Second Edition is a powerful, practical workbook by Corinne Wohl, MHSA, COE and John B. Pinto designed to take ophthalmic administrators and practice managers to the next level of their careers, offering practical tips, concrete advice, and a step-by-step guide for any hurdle they face. Available now for purchase at slackbooks.com/management. Receive 20% off with promo code PINTO20.

We'd love to hear from you! Send your comments/questions to Dr. Mali at [email protected]. Follow us on Twitter @Healio_OSN.

Disclosures: The Wyanoke Group is the parent company of Healio and SLACK Books. Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron.

In this second episode of a three-part series, John B. Pinto discusses the job market for early-career professionals and new graduates, his perspective on what ophthalmologists have learned from the pandemic and the role telemedicine will play in the future of ophthalmology.

• Intro :14
• What is the current negotiation position in the market for early-career and new graduate ophthalmic practice physicians? :41
• I'd love to hear your perspective on what we have learned about our practices after a year of this pandemic 3:35
• How is the telemedicine trend going now? Is telemedicine here to stay? 11:09
• Tell us about your upcoming book and your insight into it? 12:59
• Stay tuned for the next episode of this special three-part miniseries 17:38

John B. Pinto is president of J. Pinto & Associates, Inc. He is also a practice consultant and the author of several books on ophthalmic practice management, including John Pinto's Little Green Book of Ophthalmology, UP (with Corinne Wohl), Simple, and Ophthalmic Leadership.

UP: Taking Ophthalmic Administrators and Their Management Teams to the Next Level of Skill, Performance and Career Satisfaction, Second Edition is a powerful, practical workbook by Corinne Wohl, MHSA, COE and John B. Pinto designed to take ophthalmic administrators and practice managers to the next level of their careers, offering practical tips, concrete advice, and a step-by-step guide for any hurdle they face. Available now for purchase at slackbooks.com/management. Receive 20% off with promo code PINTO20.

We'd love to hear from you! Send your comments/questions to Dr. Mali at [email protected]. Follow us on Twitter @Healio_OSN.

Disclosures: The Wyanoke Group is the parent company of Healio and SLACK Books. Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron.

In this episode, the first of a three-part series, John B. Pinto discusses how he got started in ophthalmic practice management, shares an historical perspective on the field, plus his advice for physicians.

• Intro :16
• About John Pinto :54
• On Pinto's background, why he went into the ophthalmic practice management industry 1:39
• Can you give listeners a historical perspective of how has ophthalmic practice management changed or evolved over the last 40 years? 7:13
• What is the current state of ophthalmic practice management in America today? 13:11
• Could you give a key pearl for how to handle practice management as an early- or mid-career physician as well as a late-career/ retirement-age physician? 16:02
• In your experience, what would you say would be the average age of full retirement in ophthalmology? 23:56
• Stay tuned for the next episode of this special three-part miniseries 27:19

John B. Pinto is president of J. Pinto & Associates, Inc. He is also a practice consultant and the author of several books on ophthalmic practice management, including John Pinto's Little Green Book of Ophthalmology, UP (with Corinne Wohl), Simple, and Ophthalmic Leadership.

UP: Taking Ophthalmic Administrators and Their Management Teams to the Next Level of Skill, Performance and Career Satisfaction, Second Edition is a powerful, practical workbook by Corinne Wohl, MHSA, COE and John B. Pinto designed to take ophthalmic administrators and practice managers to the next level of their careers, offering practical tips, concrete advice, and a step-by-step guide for any hurdle they face. Available now for purchase at slackbooks.com/management. Receive 20% off with promo code PINTO20.

We'd love to hear from you! Send your comments/questions to Dr. Mali at [email protected]. Follow us on Twitter @Healio_OSN.

Disclosures: The Wyanoke Group is the parent company of Healio and SLACK Books. Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron.

In this episode, Rick Eiswirth, president and CEO of Alimera Sciences, shares the latest on the phase 4 New Day study of Iluvien, as well as his predictions for the future of ophthalmology.

• Intro :13
• In this episode :18
• About Rick Eiswirth :23
• What's your background? How did you get into the ophthalmology industry? 0:51
• What are the benefits of Iluvien (fluocinolone acetonide intravitreal implant, Alimera Sciences)? Is this an ideal treatment for 2021? 3:36
• How do you get retina specialists more onboard with using intravitreal steroids earlier, given anti-VEGFs' predominance? 6:26
• Can you tell us more about the New Day trial? 8:10
• Which trial outcome would be considered a success for Iluvien? 11:58
• Do you anticipate a cost savings? 13:58
• What's the status of the New Day trial? 15:15
• How has COVID changed the industry landscape in ophthalmology? 16:20
• Are there any new products in the pipeline? 18:38
• Iluvien is approved in other countries for uveitis 20:36
• What have you seen from retina specialists; are there longer efficacy rates? 22:10
• What do you think is the most important challenge the ophthalmic community will face in the future? 23:17
• Thanks for listening 24:36

Rick Eiswirth is president and CEO of Alimera Sciences.

We'd love to hear from you! Send your comments/questions to Dr. Mali at [email protected]. Follow us on Twitter @Healio_OSN.

Disclosures: Eiswirth is president and CEO of Alimera Sciences. Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. McCabe reports consultant relationships with Alcon, Allergan, Bausch and Lomb, Dompe, EyePoint Pharmaceuticals, Ivantis, Novartis, Ocular Therapeutix, Omeros, Sight Sciences and Zeiss. She reports research roles with Alcon, Allergan, Bausch and Lomb, EyePoint Pharmaceuticals, Glaukos, Ivantis, Johnson & Johnson, Ocular Therapeutix and Ora. She also reports an investor relationship with Ocular Innovations.

In this episode, Cathleen M. McCabe, MD, chief medical officer of Eye Health America, shares her insights and perspectives on intraocular lenses, MIGS, dry eye and more.

• Intro :14
• In this episode :21
• About Cathleen M. McCabe, MD :28
• What is your favorite intraocular lens implant to use and why? 2:24
• What is your favorite minimally invasive glaucoma surgery (MIGS) to use and why? 4:03
• What is your favorite dry-eye treatment to use and why? 4:49
• What's your preferred technique for secondary IOLs? 6:29
• How has the role of women in ophthalmology changed throughout the years? 8:46
• How did you get involved with international work? How has the pandemic affected this? 10:55
• Tell us about your mission work. What are you currently involved in? 12:54
• What is the most important topic/issue/challenge facing ophthalmology now or in the future? 15:11
• Final words from Dr. McCabe 16:46

Cathleen M. McCabe, MD, is chief medical officer of Eye Health America; medical director of The Eye Associates and president of Outpatient Ophthalmic Surgery Society.

We'd love to hear from you! Send your comments/questions to Dr. Mali at [email protected]. Follow us on Twitter @Healio_OSN.

To learn more about the Global Education & Research Society of Ophthalmology (or GERSO), visit https://www.gerso.org.

Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. McCabe reports consultant relationships with Alcon, Allergan, Bausch and Lomb, Dompe, EyePoint Pharmaceuticals, Ivantis, Novartis, Ocular Therapeutix, Omeros, Sight Sciences and Zeiss. She reports research roles with Alcon, Allergan, Bausch and Lomb, EyePoint Pharmaceuticals, Glaukos, Ivantis, Johnson & Johnson, Ocular Therapeutix and Ora. She also reports an investor relationship with Ocular Innovations.